How to Land a Deal with Big Pharma
Big pharma companies are investing heavily in external innovation, seeking licensing deals and acquisition targets in the biotech industry.
Due to pending losses of exclusivity and an uncertain policy environment, pharma companies are looking to make strategic investments that yield significant returns.
"I think what we're seeing is, yes, there's capital, but it's isolated to a more select group of biotech companies,"
according to Steven Ladd, vice president of business development and acquisitions at BeOne Medicines. He notes that companies with differentiated data are the most attractive to large pharma.
- Big pharma companies are seeking innovative biotech companies for partnerships.
- Start-ups face challenges, but this can create opportunities for both parties.
Author's summary: Big pharma seeks innovative biotech deals.